Anastrozole vs Testosterone Cypionate
A side-by-side research comparison of Anastrozole and Testosterone Cypionate across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Anastrozole | Testosterone Cypionate |
|---|---|---|
| Full name | Anastrozole (Arimidex) | Testosterone Cypionate (Depo-Testosterone) |
| Category | Hormone Replacement | Hormone Replacement |
| Status | FDA-approved prescription | FDA Approved (Schedule III) |
| Mechanism | Selectively and reversibly inhibits aromatase (CYP19A1), the enzyme that converts androgens to estrogens. Reduces circulating estradiol levels without affecting other steroid pathways. | Exogenous testosterone binds androgen receptors in muscle, bone, brain, and reproductive tissues. The cypionate ester provides slow release from the injection depot, maintaining physiologic levels between doses. |
| Molecular weight | 293.37 Da | 412.61 Da |
| Half-life | ~46.8 hours | ~8 days |
| Bioavailability | ~80-85% oral | ~100% (intramuscular) |
| Typical dose | 0.25-0.5 mg | 100-200 mg |
| Frequency | 2-3x per week | Weekly or split biweekly |
| Route | Oral tablet | Intramuscular or subcutaneous injection |
Anastrozole reported benefits
- Estrogen control
- Reduced water retention
- Prevention of gynecomastia
- Maintained testosterone ratio
- Improved body composition
Testosterone Cypionate reported benefits
- Restored libido and sexual function
- Increased lean muscle mass
- Improved bone density
- Enhanced mood and cognitive clarity
- Reduced visceral fat
- Improved energy and motivation
Related comparisons
Research and educational reference only. Not medical advice.